Eric Sasso, MD, Vice President, Medical and Scientific Affairs, Crescendo Bioscience, describes the benefits of the Vectra DA test in predicting a patient’s risk for future joint damage. The Vectra DA test is currently being used by 40 percent of American rheumatologists, providing them with useful information that results in a more appropriate treatment option for the patient. Another benefit of the Vectra DA test is identifying inflammation caused by rheumatoid arthritis, both helping physicians prevent joint damage and avoid unnecessary anti-inflammatory treatment.
Resources & References:
Eric Sasso, MD
Salary: Crescendo Bioscience
Ownership Interest: Myriad Genetics